Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium Inc. (EQ) is a clinical-stage biotechnology company pioneering therapies for severe autoimmune and inflammatory disorders. This news hub provides investors and stakeholders with timely updates on EQ's scientific advancements, regulatory milestones, and corporate developments.
Access curated press releases and analysis covering key areas including clinical trial results, regulatory communications, research partnerships, and financial performance updates. Our repository simplifies tracking of EQ's novel therapeutic candidates like itolizumab (anti-CD6) and cytokine inhibitors in development.
Bookmark this page for streamlined monitoring of Equillium's progress in addressing conditions such as graft-versus-host disease and lupus nephritis through immunomodulatory approaches. Return regularly for verified updates directly from company filings and authorized sources.
Equillium, Inc. (Nasdaq: EQ) reported a net loss of $29.8 million for 2020, or $(1.46) per share, an increase from a $25.6 million loss in 2019. R&D expenses rose to $19.4 million, reflecting increased headcount and research costs. In 2021, the company announced positive interim data from the EQUATE study for aGVHD and raised $83.7 million in 2020, extending its cash runway into the second half of 2023. Upcoming data from clinical studies in lupus, uncontrolled asthma, and aGVHD is anticipated in 2021, signaling potential growth catalysts for stakeholders.
Equillium, Inc. (Nasdaq: EQ) announced positive results from its EQUATE study on itolizumab, a treatment for acute graft-versus-host disease (aGVHD). Most patients achieved a complete response within 15 days, maintained through day 85, with a significant 91% reduction in corticosteroid use. The study highlights itolizumab's potential as a first-line treatment, underlining its dose-dependent effectiveness in inhibiting pathogenic T cell proliferation. Translational data supports its role in modulating T cell activity, indicating promising future applications in severe autoimmune disorders.
Equillium, Inc. (Nasdaq: EQ) announced its participation in the H.C. Wainwright Global Life Sciences Conference on March 9, 2021. Jason Keyes, the Chief Financial Officer, will discuss ongoing clinical programs targeting acute graft-versus-host disease, lupus/lupus nephritis, and uncontrolled asthma. Attendees can engage in one-on-one meetings with Equillium's leadership during the event. A webcast of the presentation will be accessible for 90 days on their website. Equillium specializes in developing treatments for severe autoimmune disorders.
Equillium, Inc. (Nasdaq: EQ) announced its participation in the SVB Leerink 10th Annual Global Healthcare Conference from February 22-26, 2021. The presentation will take place on February 25 at 11:20 AM ET, covering ongoing clinical programs for itolizumab in treating severe autoimmune disorders, including acute graft-versus-host disease and lupus. A live webcast will be available on the company’s website, with an archived replay accessible for 90 days. Equillium focuses on developing innovative treatments for severe immuno-inflammatory diseases.
Equillium, Inc. (Nasdaq: EQ) announced interim data from the EQUATE clinical trial, showcasing the efficacy of itolizumab as a first-line treatment for acute graft-versus-host disease (aGVHD). Presented by Dr. John Koreth, the findings revealed a remarkable 100% overall response rate in higher dose cohorts, alongside a significant reduction in corticosteroid use by 40-80%. The trial demonstrated itolizumab's safety profile and its mechanism of action, with sustained clinical responses through Day 57. The company anticipates topline results later this year.
Equillium, Inc. (Nasdaq: EQ) appointed Dr. Y. Katherine Xu to its board of directors, effective February 4, 2021. A partner at Decheng Capital, Dr. Xu brings extensive experience in biotechnology and finance. Her expertise is expected to enhance Equillium’s strategic direction as the company advances into later-stage development of itolizumab, aimed at treating severe autoimmune disorders. Dr. Xu noted the significance of targeting the CD6-ALCAM pathway, particularly after promising interim results for treating acute graft-versus-host disease.
Equillium, Inc. (Nasdaq: EQ) has successfully closed a registered direct offering, raising approximately $30 million in gross proceeds. The offering included 4,285,710 units, with each unit comprising one share of common stock and a warrant for an additional 0.3 shares, priced at $7.00 per unit. The exercise price of the warrants is set at $14.00 per share. Proceeds from this offering will primarily fund the development of the itolizumab pipeline, potential acquisitions, and general corporate purposes.
Equillium, Inc. (Nasdaq: EQ) announced a securities purchase agreement to sell 4,285,710 units at $7.00 each, raising approximately $30 million. Each unit consists of one share of common stock and a warrant for 0.3 additional shares at an exercise price of $14.00. The funds will be used for developing the itolizumab pipeline, acquiring new products, and general corporate needs. The offering closes on February 5, 2021. This offering is registered under a shelf registration statement with the SEC.
Equillium, Inc. (Nasdaq: EQ) announced that interim data from its Phase 1b/2 EQUATE study of itolizumab for acute graft-versus-host disease (aGVHD) will be presented as a late-breaking oral session at the 2021 TCT Meetings, scheduled for February 12, 2021. The study, led by John Koreth, aims to demonstrate the safety and efficacy of itolizumab, a first-in-class monoclonal antibody that targets the CD6-ALCAM pathway, important in T cell activity related to autoimmune disorders. Equillium is focused on treating severe autoimmune and inflammatory conditions with high unmet medical needs.
Equillium, a clinical-stage biotechnology company, announced that its CEO Bruce Steel will present at the H.C. Wainwright Virtual BioConnect Conference on January 11, 2021, at 6:00 am EST. This presentation will focus on itolizumab, a treatment for severe autoimmune and inflammatory disorders. A webcast of the presentation will be accessible on the company’s website under the “Investors” section for 30 days following the event.
Equillium is dedicated to addressing high unmet medical needs in severe immuno-inflammatory diseases.
